Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Andrew Galazka"'
Autor:
Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T. Reder
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 283-322 (2024)
Abstract Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurr
Externí odkaz:
https://doaj.org/article/8f4b63ea68774d85b40c2425f80dbef2
Autor:
Gavin Giovannoni, Patricia K. Coyle, Patrick Vermersch, Bryan Walker, Julie Aldridge, Axel Nolting, Andrew Galazka, Caroline Lemieux, Thomas P. Leist
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cladribine tablets (CladT) preferentially reduce B and T lymphocyte levels. As aging is associated with a decline in immune function, the effect of CladT on lymphocyte levels may differ by age. This post hoc analysis combined data from the Phase 3 CL
Externí odkaz:
https://doaj.org/article/dd0a2bfca3cd4d47a0bd4b2a7dcbf98d
Autor:
Robert Hermann, Peter Krajcsi, Markus Fluck, Annick Seithel-Keuth, Afrim Bytyqi, Andrew Galazka, Alain Munafo
Publikováno v:
Clinical Pharmacokinetics. 61:167-187
Cladribine is a nucleoside analog that is phosphorylated in its target cells (B and T-lymphocytes) to its active triphosphate form (2-chlorodeoxyadenosine triphosphate). Cladribine tablets 10 mg (Mavenclad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f6cd2fe6e73e87495f734393ce868c0
https://doi.org/10.1007/s40262-021-01089-9
https://doi.org/10.1007/s40262-021-01089-9
Autor:
Andrew Galazka, Peter Krajcsi, Alain Munafo, Markus Fluck, Annick Seithel-Keuth, Robert Hermann, Afrim Bytyqi
Publikováno v:
Clinical Pharmacokinetics
Cladribine is a nucleoside analog that is phosphorylated in its target cells (B- and T-lymphocytes) to its active adenosine triphosphate form (2-chlorodeoxyadenosine triphosphate). Cladribine tablets 10 mg (Mavenclad®) administered for up to 10 days
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de91223e03a7f87c1ca37b6d68eeaec5
http://europepmc.org/articles/PMC8613159
http://europepmc.org/articles/PMC8613159
Autor:
Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas P Leist, Patricia K Coyle, Fernando Dangond, Nektaria Alexandri, Andrew Galazka
Publikováno v:
Neurodegenerative disease management. 12(6)
What is this summary about? This is a summary of an article originally published in the Multiple Sclerosis Journal. The article presents the results from the CLARITY and CLARITY Extension studies, which looked at how well cladribine tablets work in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4151f2f3931895a929998991db9064ba
https://pubmed.ncbi.nlm.nih.gov/36017797
https://pubmed.ncbi.nlm.nih.gov/36017797
Autor:
Gavin Giovannoni, Patricia K. Coyle, Andrew Galazka, Thomas Leist, Nektaria Alexandri, Fernando Dangond, B. Keller, Kottil Rammohan, Maria Pia Sormani, Nicola De Stefano
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study of patients with relapsing-remitting multiple sclerosis, treatment with cladribine tablets 3.5 mg/kg (CladT) significantly reduced the annualised relapse rate (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf8cb96eae26b3d90b6e16cab1eba15
https://doi.org/10.1177/13524585211010294
https://doi.org/10.1177/13524585211010294
Autor:
Doris Damian, Schiffon L. Wong, Gerard Harty, Fernando Dangond, Dominic Jack, Patrick Vermersch, Andrew Galazka
Publikováno v:
Current Medical Research and Opinion. 37:459-464
Relapsing–remitting multiple sclerosis (RRMS) patients with high disease activity (HDA) experience more severe disease than those without HDA. This analysis describes the efficacy of cladribine tab...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58e4a4a990f8bb3498355c99371ab85e
https://doi.org/10.1080/03007995.2020.1865888
https://doi.org/10.1080/03007995.2020.1865888
Autor:
Fernando Dangond, Kottil Rammohan, Thomas Leist, Megan Grosso, Patricia K. Coyle, Andrew Galazka, Elke Sylvester
Publikováno v:
Drugs
Cladribine is a purine nucleoside analog initially developed in the 1970s as a treatment for various blood cancers. Due to the molecule’s ability to preferentially reduce T and B lymphocytes, it has been developed into an oral formulation for the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68816b45afd0b500241c1d8ba04fb10e
https://doi.org/10.1007/s40265-020-01422-9
https://doi.org/10.1007/s40265-020-01422-9
Publikováno v:
Multiple Sclerosis and Related Disorders
Background We previously summarized outcomes for 46 cladribine tablets (CladT)-treated patients with multiple sclerosis (MS) and confirmed or suspected COVID-19, as reported to the Merck KGaA Global Patient Safety Database. This report updates on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5a19084be94985d00f33c67b68cfd5
https://pubmed.ncbi.nlm.nih.gov/33813097
https://pubmed.ncbi.nlm.nih.gov/33813097
Publikováno v:
Multiple Sclerosis and Related Disorders
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966c4f9bc9601aa48ebfb13f1685fac4